

Imugene Files New HER-Vaxx Patent

- **HER-Vaxx patent life potentially extended to 2036**
- **Up to six additional years of peak sales**

Melbourne, April 21 2015: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company developing HER-2 positive gastric and breast cancer immunotherapies, announces today the filing of a new provisional patent titled "*A Vaccine Composition and Uses Thereof*" (application number 2015901375), potentially extending HER-Vaxx patent life to 2036.

This new filing protects innovative new vaccine formulations designed to enhance the immune response obtained on administration of HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response in patients with HER-2 positive cancers. The enhanced formulation of HER-Vaxx incorporates an existing, clinically and commercially validated vaccine carrier protein called CRM197 together with an adjuvant.

Imugene's Managing Director Charles Walker said, "Maintaining and strengthening our already strong international intellectual property position is a key area of focus in maintaining the competitive advantage of HER-Vaxx and any future improvements, vaccine formulations and clinical uses. We are extremely pleased with the progress made from our expert scientific team."

"This new patent filing potentially protects HER-Vaxx until 2036 which would be significantly longer than the vast majority of competing clinical stage products and technologies. The additional patent life adds an additional six years to the time HER-Vaxx could remain generating peak sales, adding to the total amount of potential sales achievable by HER-Vaxx and hence significantly increasing the value of HER-Vaxx" Mr. Walker added.

About Imugene:

Imugene (ASX; IMU) is a clinical stage immuno-oncology company developing HER-2+ gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER-2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase 1 study in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.

Charles Walker **Managing Director**

Tel: +61 (0) 4 5044 6990
cwalker[at]imugene.com
www.imugene.com

Media contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

Paul Hopper (Los Angeles) **Executive Chairman**

Tel: +1 858 334 5820 (US)
Tel: +61 406 671 515 (Australia)
receptogen[at]earthlink.net

Stephanie Carrington (NYC)

Integrated Corporate Relations (ICR)
Ph: 646-277-1282
stephanie.carrington@icrinc.com